Enteral hydration in high-flow therapy for infants with bronchiolitis: Secondary analysis of a randomised trial
Franz E Babl, Donna Franklin, Luregn J Schlapbach, Ed Oakley, Stuart Dalziel, Jennifer A Whitty, Jocelyn Neutze, Jeremy Furyk, Simon Craig, John F Fraser, Mark Jones, Andreas Schibler
Journal of Paediatrics and Child Health | WILEY | Published : 2020
AIM: Nasal high-flow oxygen therapy is increasingly used in infants for supportive respiratory therapy in bronchiolitis. It is unclear whether enteral hydration is safe in children receiving high-flow. METHODS: We performed a planned secondary analysis of a multi-centre, randomised controlled trial of infants aged <12 months with bronchiolitis and an oxygen requirement. Children were assigned to treatment with either high-flow or standard-oxygen therapy with optional rescue high-flow. We assessed adverse events based on how children on high-flow were hydrated: intravenously (IV), via bolus or continuous nasogastric tube (NGT) or orally. RESULTS: A total of 505 patients on high-flow via prima..View full abstract
Awarded by National Health and Medical Research Council (NHMRC), Canberra, Australia
Awarded by National Health and Medical Research Council Centre of Research Excellence grant for paediatric emergency medicine
The study was funded by a project grant from the National Health and Medical Research Council (NHMRC, GNT1081736), Canberra, Australia, and the Emergency Medicine Foundation, Brisbane, Australia. Regional site funding was obtained for Ipswich Hospital from the Ipswich Hospital Foundation and the Gold Coast University Hospital (GCUH) from the GCUH Foundation. A Schibler and JF Fraser received a research fellowship from the Queensland Health Department, Australia. PREDICT sites were supported by a National Health and Medical Research Council Centre of Research Excellence grant for paediatric emergency medicine (GNT1058560). Victorian sites received infrastructure support from the Victorian Government's Infrastructure Support Program, Melbourne, Australia. FE Babl was part funded by a Royal Children's Hospital Foundation grant, a Melbourne Campus Clinician Scientist Fellowship, Melbourne, Australia and an NHMRC Practitioner Fellowship. S Dalziel was part funded by a grant from the Health Research Council of New Zealand (HRC), Auckland, New Zealand. The Townsville Hospital was part funded by a SERTA grant (Study, Education and Research Trust Account). The high-flow equipment and consumables for all study sites were provided free of charge by Fisher and Paykel Healthcare (Auckland, New Zealand), who had no involvement in design, conduct, and analysis of the study. D Franklin, S Dalziel, JF Fraser and A Schibler received travel support from Fisher and Paykel Healthcare. JF Fraser reports research grant support by Fisher and Paykel Healthcare.